|
|
|
27.05.26 - 07:30
|
CSPC PHARMA Tumbles ~8% as 1Q Profit Slides 40% YoY (AAStocks)
|
|
|
CSPC PHARMA (01093.HK) closed at HKD7.26 at midday, down 2.42%. After announcing at noon that its 1Q26 profit declined by 40% YoY, the stock extended losses in the afternoon and last posted at HKD6.86, down 7.8%, with turnover of 64.4347 million shares, involving HKD462 million.~AASTOCKS Financial NewsWebsite: www.aastocks.com...
|
|
|
27.05.26 - 06:30
|
CSPC PHARMA 1Q26 Basic Profit Falls 40.3% YoY to RMB842 million (AAStocks)
|
|
|
CSPC PHARMA (01093.HK) announced its results for 1Q26 ended March. Revenue amounted to RMB6.465 billion, down 7.8% YoY. Net profit was RMB860 million, down 41.8% YoY; EPS was RMB0.0754.During the period, excluding fair value changes of financial assets at fair value through profit or loss and share-based employee compensation ex......
|
|
|
|
|
|
|
14.05.26 - 11:06
|
Degron Therapeutics Closes $40 Million Series A Extension to Support Molecular Glue Degrader Clinical Development (Business Wire)
|
|
|
Proceeds will support advancement of the lead HuR molecular glue degrader clinical program, progression of two immunology programs toward IND, and continued expansion of the GlueXplorer® molecular glue discovery platform
New round brings total capital raised to $95 million
Lead HuR program now in Phase 1— first-in-class molecular glue degrader targeting previously undruggable RNA-binding protein intended to treat multiple types of solid tumorsSAN DIEGO & HANGZHOU, China & SHANGHAI, China--(BUSINESS WIRE)--Degron Therapeutics ("Degron"), a clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines targeting previously undruggable or insufficiently drugged proteins, today announced the closing of a $40 million Series A Extension. The round was led by LAPAM CAPITAL. Additional investors include GTJA Investment Group, Fortune Capital, CSPC & Growth, ApicHope, GF Xinde, CASSTAR, Kinghall Ventures, and GAGE Capital. This brings Degron's total capital raised to $95 milli...
|
|
|
|
|
|
|
29.04.26 - 16:30
|
CSPC PHARMA SYS6051 Receives US FDA Approval to Commence Clinical Trials (AAStocks)
|
|
|
CSPC PHARMA (01093.HK) announced that SYS6051, an antibody-drug conjugate (ADC) developed by the Group, has received approval from the US Food and Drug Administration (FDA) to commence clinical trials. The approved indication for this trial is advanced solid tumors.SYS6051 is an antibody-drug conjugate targeting human tissue fac......
|
|
|
|
|
|
|
|
|
|
|
18.04.26 - 05:00
|
As China′s biotech firms shift gears, can AI floor the accelerator? (SCMP)
|
|
|
A quarter featuring multiple eye-popping deals is no longer unusual for China's pharmaceutical industry – in fact, it may soon be considered a slow season.
In recent months, companies including CSPC Pharmaceutical and RemeGen have struck out-licensing agreements worth up to US$18.5 billion and US$5.6 billion respectively, while Haisco Pharmaceutical Group has added two of its own — most recently a deal worth up to US$745 million.
Under the terms of the deal, the Beijing-based Haisco granted US......
|
|
|
15.04.26 - 11:45
|
CSPC PHARMA SYS6051 Drug Approved for Clinical Trials in China (AAStocks)
|
|
|
CSPC PHARMA (01093.HK) announced that SYS6051, developed by the group, has been approved by the National Medical Products Administration to commence clinical trials in China. The product is an antibody-drug conjugate targeting human tissue factor. It binds to tissue factor on the surface of tumor cells, enters the cells through ......
|
|
|
|
|
|
|
|
|
27.03.26 - 10:00
|
H Shrs: HSI Rises 95 Points Led by Pharma Stocks; CSPC Surges Nearly 14% (AAStocks)
|
|
|
US President Donald Trump extended the suspension of attacks on Iranian energy facilities until the 6th of next month, leading to a volatile rise in Hong Kong stocks. The HSI opened 87 points lower and initially fell 143 points to a low of 24,712 points, then rose 239 points to a high of 25,095 points, closing up 95 points or 0.......
|
|
|
27.03.26 - 06:00
|
H Shrs: HSI Rises 135 Points at Midday; BYD Surges Over 4%, CSPC Gains 10% (AAStocks)
|
|
|
US President Donald Trump extended the suspension of attacks on Iranian energy facilities until the 6th of next month, leading to a rise in the Hong Kong stock market in the morning session. The HSI opened 87 points lower and fluctuated, dropping 143 points to 24,712 points before closing at nearly the peak of 24,992 points at m......
|
|
|
27.03.26 - 05:15
|
Midday Takeaway: HSI Closes Midday at 24,992, Up 135 pts; HSTI Closes Midday at 4,811, Up 50 pts; CSPC PHARMA Up over 9%; XUNCE, WASION HOLDINGS, GANFENGLITHIUM, QINGSONG HEALTH, HUISHANG BANK Hit New Highs (AAStocks)
|
|
|
At midday close, HSI rose 135 pts or 0.5% to 24,992. HSTI rose 50 pts or 1.1% to 4,811. HSCEI gained 79 pts or 1.0% to 8,469.Active Heavyweights:MEITUAN (03690.HK) closed at $88.15, up 1.7%XIAOMI (01810.HK) closed at $32.98, up 1.7%BABA (09988.HK) closed at $123.4, up 0.3%TENCENT (00700.HK) closed at $495, down 0.1%HSI & HSCEI C......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
